MENLO PARK, Calif., March 22, 2019 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ: DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living with chronic skin conditions, today announced the closing of its previously announced underwritten public offering of 11,283,019 shares of its common stock, including 1,471,698 shares sold upon full exercise of the underwriters’ option to purchase additional shares of common stock, at a price to the public of $13.25 per share. All of the shares were sold by Dermira. The aggregate gross proceeds to Dermira from the offering, before deducting the underwriting discounts and commissions and offering expenses, were approximately $149.5 million.
Citigroup, Cowen, Cantor Fitzgerald & Co. and Guggenheim Securities acted as book-runners for the offering. Needham & Company and H.C. Wainwright & Co. acted as co-managers.
The public offering was made pursuant to a shelf registration statement on Form S-3 that was filed by Dermira with the Securities and Exchange Commission (“SEC”) on November 7, 2018 and was declared effective on November 21, 2018. This offering was made solely by means of a prospectus supplement and accompanying prospectus relating to and describing the terms of the offering, copies of which may be obtained from Citigroup Global Markets Inc., c/o Broadridge Financial Solutions, Attention: Prospectus Department, 1155 Long Island Avenue, Edgewood, NY 11717, or by telephone at 800-831-9146; Cowen and Company, LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by telephone at 631-274-2806; Cantor Fitzgerald & Co., Attention: Capital Markets, 499 Park Avenue, 6th Floor, New York, NY 10022, or by email at firstname.lastname@example.org; and Guggenheim Securities, LLC, Attention: Equity Syndicate Department, 330 Madison Avenue, 8th Floor, New York, NY 10017, by telephone at 212-518-9658, or by email at GSEquityProspectusDelivery@guggenheimpartners.com.
This press release shall not constitute an offer to sell or a solicitation of an offer to buy Dermira’s common stock, nor shall there be any sale of Dermira’s common stock in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
Vice President, Corporate Communications
Ian Clements, Ph.D.
Vice President, Investor Relations
Source: Dermira, Inc.